Literature DB >> 18025284

Conjugation of an anti transferrin receptor IgG3-avidin fusion protein with biotinylated saporin results in significant enhancement of its cytotoxicity against malignant hematopoietic cells.

Tracy R Daniels1, Patrick P Ng, Tracie Delgado, Maureen R Lynch, Gary Schiller, Gustavo Helguera, Manuel L Penichet.   

Abstract

We have previously developed an antibody fusion protein composed of a mouse/human chimeric IgG3 specific for the human transferrin receptor genetically fused to avidin (anti-hTfR IgG3-Av) as a universal delivery system for cancer therapy. This fusion protein efficiently delivers biotinylated FITC into cancer cells via TfR-mediated endocytosis. In addition, anti-hTfR IgG3-Av alone exhibits intrinsic cytotoxic activity and interferes with hTfR recycling, leading to the rapid degradation of the TfR and lethal iron deprivation in certain malignant B-cell lines. We now report on the cytotoxic effects of a conjugate composed of anti-hTfR IgG3-Av and biotinylated saporin 6 (b-SO6), a toxin derived from the plant Saponaria officinalis that inhibits protein synthesis. Conjugation of anti-hTfR IgG3-Av with b-SO6 enhances the cytotoxic effect of the fusion protein in sensitive cells and also overcomes the resistance of malignant cells that show low sensitivity to the fusion protein alone. Our results show for the first time that loading anti-hTfR IgG3-Av with a biotinylated toxin enhances the cytotoxicity of the fusion protein alone. These results suggest that anti-hTfR IgG3-Av has great potential as a therapeutic agent for a wide range of applications due to its intrinsic cytotoxic activity plus its ability to deliver biotinylated molecules into cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025284     DOI: 10.1158/1535-7163.MCT-07-0330

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  21 in total

1.  Inhibition of NF-kappaB and Akt pathways by an antibody-avidin fusion protein sensitizes malignant B-cells to cisplatin-induced apoptosis.

Authors:  Eriko Suzuki; Tracy R Daniels; Gustavo Helguera; Manuel L Penichet; Kazuo Umezawa; Benjamin Bonavida
Journal:  Int J Oncol       Date:  2010-05       Impact factor: 5.650

2.  Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma.

Authors:  Lai Sum Leoh; Yoon Kyung Kim; Pierre V Candelaria; Otoniel Martínez-Maza; Tracy R Daniels-Wells; Manuel L Penichet
Journal:  J Immunol       Date:  2018-04-13       Impact factor: 5.422

3.  An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.

Authors:  Tracy R Daniels; Elizabeth Ortiz-Sánchez; Rosendo Luria-Pérez; Rafaela Quintero; Gustavo Helguera; Benjamin Bonavida; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

Review 4.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer.

Authors:  Tracy R Daniels; Ezequiel Bernabeu; José A Rodríguez; Shabnum Patel; Maggie Kozman; Diego A Chiappetta; Eggehard Holler; Julia Y Ljubimova; Gustavo Helguera; Manuel L Penichet
Journal:  Biochim Biophys Acta       Date:  2011-08-05

5.  Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter.

Authors:  Lai Sum Leoh; Kouki Morizono; Kathleen M Kershaw; Irvin S Y Chen; Manuel L Penichet; Tracy R Daniels-Wells
Journal:  J Gene Med       Date:  2014 Jan-Feb       Impact factor: 4.565

Review 6.  Self-assembled lipid nanomedicines for siRNA tumor targeting.

Authors:  Yu-Cheng Tseng; Leaf Huang
Journal:  J Biomed Nanotechnol       Date:  2009-08       Impact factor: 4.099

Review 7.  Transferrin receptor-mediated endocytosis: a useful target for cancer therapy.

Authors:  Stephanie Tortorella; Tom C Karagiannis
Journal:  J Membr Biol       Date:  2014-02-27       Impact factor: 1.843

8.  Efficacy of an Anti-transferrin Receptor 1 Antibody Against AIDS-related Non-Hodgkin Lymphoma: A Brief Communication.

Authors:  Tracy R Daniels-Wells; Daniel P Widney; Lai Sum Leoh; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2015-10       Impact factor: 4.456

9.  Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.

Authors:  Hui Ding; Gustavo Helguera; José A Rodríguez; Janet Markman; Rosendo Luria-Pérez; Pallavi Gangalum; Jose Portilla-Arias; Satoshi Inoue; Tracy R Daniels-Wells; Keith Black; Eggehard Holler; Manuel L Penichet; Julia Y Ljubimova
Journal:  J Control Release       Date:  2013-06-12       Impact factor: 9.776

Review 10.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.